A vaccine is a biological preparation that strengthens the immune system and provides acquired immunity against a specific pathogen. According to the World Health Organization (WHO), cancer vaccines are popularly for treating various types of cancer such as, breast cancer, lung cancer, cervical cancer, and others. The key factors that driving the market growth include rise in prevalence of human papilloma virus (HPV) infections leading to cancers, increase in administration of prophylactic cancer vaccines, surge in investments in the development of cancer vaccines by manufacturers & governmental funding, and launch & approval of novel cancer vaccines in the market. The global cancer vaccines market was valued at $4,073 million in 2016, and is expected to reach at $12,814 million by 2023, registering a CAGR of 17.7% from 2017 to 2023.

The global cancer vaccines market is segmented based on technology, indication, type end use, and region. Based on technology, it is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, and viral vector & DNA cancer vaccines. Based on indication, it is bifurcated into cervical cancer, prostate cancer, and others. On the basis of end use, it is classified into pediatric vaccines and adult vaccines. Based on type, the market is divided into therapeutic cancer vaccines and preventive cancer vaccines.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the increase in prevalence of cervical cancers, rise in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements in vaccine administration. However, Asia-Pacific is expected to witness maximum growth potential, due to the improvement in healthcare facilities, high disposable income, and rapid development of economic conditions.


Key benefits

The study provides an in-depth analysis of the global cancer vaccines market with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry to understand the type of products and technologies used globally.
Key market players and their strategies are provided to understand the competitive outlook of the market.
KEY MARKET SEGMENTS

BY TECHNOLOGY

Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Whole Cell Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
BY TYPE

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
BY INDICATION

Cervical Cancer
Prostate Cancer
Others
BY END USE

Pediatrics
Adults
BY REGION

North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Turkey
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED

AstraZeneca PLC. (Medimmune, LLC.)
Glaxosmithkline Plc.
Merck & Co., Inc.
Sanofi Pasteur
Aduro BioTech Inc.
Astellas Pharma Inc.
CSL Limited
Pfizer Inc.
Sanpower Group
Serum Institute of India Pvt. Ltd.
The other players in the value chain include (profiles not included in the report)

Gritstone Oncology
PaxVax Corporation.
Bavarian Nordic
Bharat Biotech.
VBI Vaccines Inc.
Novavax, Inc.
Dynavax Technologies Corporation
Immunomic Therapeutics, Inc.
Gamma Vaccines Pty Limited
Sinovac Biotech Ltd.
Prokarium
ImmunoBiology Ltd.
Galena Biopharma